Four Decades for Justice
Cravath represented the underwriters, J.P. Morgan Securities, Leerink Partners and BMO Capital Markets, in connection with the $111 million initial public offering of the common stock of Replimune Group, Inc., a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform. The shares were listed on the Nasdaq Global Select Market. The transaction closed on July 24, 2018.
The Cravath team included partner William V. Fogg and associates William F. Roegge and Ana Drmanovic on securities matters; partner David J. Kappos and practice area attorney Anthony N. Magistrale on intellectual property matters; associate Kiran Sheffrin on tax matters; and associate Philip F. Schreiber on executive compensation and benefits matters. Summer associate Benjamin J. Barocas also worked on securities matters.
Deals & Cases
April 15, 2024
Cravath, together with Hengeler Mueller, represented Douglas AG in connection with its €890 million initial public offering of ordinary bearer shares. The DOUGLAS Group is a leading omnichannel premium beauty destination in Europe. The shares were listed on the Frankfurt Stock Exchange (Prime Standard). The transaction closed on March 25, 2024.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.